ASBP Aspire Biopharma Holdings, ...

Nasdaq aspirebiolabs.com


$ 0.33 $ 0.02 (6.57 %)    

Friday, 17-Oct-2025 18:00:31 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.3404
$ 0.33
$ 0.31 x 500
$ 0.35 x 200
$ 0.32 - $ 0.35
$ 0.20 - $ 15.80
1,402,855
na
16.86M
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 04-07-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-16-2024 06-30-2024 10-Q
6 06-05-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-21-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-...

 crude-oil-down-2-aspire-biopharma-shares-spike-higher

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow trade...

Core News & Articles

Anticipated Upcoming MilestonesSublingual High-dose Aspirin (Lead Program)H2 2025: Request meeting with FDA to discuss 505(b)(2...

Core News & Articles

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production CapacitySupraNaturals is a lead...

Core News & Articles

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes af...

 aspire-shares-are-trading-higher-monday-whats-going-on

Aspire shares are trading higher Monday after the company announced top-line data from its crossover bioavailability trial.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION